Manoj Duggal, MD
Cardiovascular Disease · Crown Point, INNPI 1447243258
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.8%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 65.9% of it on its own, with 21 other manufacturers making up the rest. Among cardiovascular disease clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 232 payments — averaging $177.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$27K
- Boston Scientific$4K
- Abbott$3K
- Altathera Pharmaceuticals LLC$2K
- Siemens Medical Solutions USA, Inc.$2K
- Biosense Webster, Inc.$792
- plus $2K from 16 others
Across 64 payments — averaging $2192.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$120K
- Abbott$20K
- Medtronic$200
What the payments were for
- Consulting fees$18,06344%
- Speaking & faculty fees$9,00022%
- Travel & lodging$3,0557%
- Food & beverage$11,07127%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 58 | $27,129 |
| Boston Scientific | 61 | $3,878 |
| Abbott | 41 | $3,367 |
| Altathera Pharmaceuticals LLC | 3 | $2,460 |
| Siemens Medical Solutions USA, Inc. | 2 | $1,718 |
| Biosense Webster, Inc. | 22 | $792 |
| Johnson & Johnson | 15 | $358 |
| Abiomed | 1 | $271 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $257 |
| Cardiva Medical, Inc. | 3 | $245 |
| Inari Medical, Inc. | 1 | $218 |
| Atricure, Inc. | 1 | $138 |
| Philips North America LLC | 1 | $125 |
| Novartis | 4 | $76 |
| Amgen | 2 | $36 |
| AstraZeneca | 3 | $34 |
| Pfizer | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Kestra Medical Technology Services, Inc. | 1 | $15 |
| Cardinal Health 200 LLC | 1 | $14 |
| Cordis US CORP. | 1 | $14 |
| Angiodynamics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Sotalol Hydrochloride$2,460
- GENERAL - THERAPIES$985
- ENSITE PRECISION$748
- Micra$736
- Watchman$520
- EVERA MRI XT DR SURESCAN$481
- Agilis NxT EP Introducer$450
- Quadra Assura CRT Defibrillator$428
- Carto 3$330
- PulseSelect$297
- MitraClip$282
- Impella$271
- ENSITE$269
- WATCHMAN FLX$261
- Rhythmia Mapping System$251
- Cardiva VASCADE MVP VVCS 6-12F$232
- FLOWTRIEVER CATHETER, S$218
- CT THROMBECTOMY SYSTEM KIT$218
- EMBLEM MRI S-ICD$163
- AMPLATZER$153
How this compares
$41,195 in reported general payments places this provider in the 90th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 297 | $343,647 |
| XareltoRivaroxaban | 54 | $62,370 |
| MultaqDronedarone Hcl | 38 | $53,956 |
| EntrestoSacubitril/Valsartan | 13 | $23,788 |
| Metoprolol Succinate | 218 | $3,008 |
| Flecainide Acetate | 54 | $2,069 |
| Mexiletine Hcl | 16 | $1,963 |
| Amiodarone Hcl | 82 | $1,193 |
| SotalolSotalol Hcl | 51 | $1,152 |
| Diltiazem 24hr ErDiltiazem Hcl | 13 | $740 |
| Losartan Potassium | 31 | $396 |
| Pantoprazole Sodium | 13 | $393 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 19 | $392 |
| Amlodipine Besylate | 27 | $302 |
| Furosemide | 34 | $206 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $20 | $343,647297 claims |
| Johnson & JohnsonXarelto | $358 | $62,37054 claims |
| NovartisEntresto | $76 | $23,78813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Crown Point
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Wai LeeElkhart$321K
- Anas SafadiHobart$295K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
- Christopher HealyIndianapolis$209K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.